vs Neblina Uacari

Clitopilus passeckerianus compared with Cacajao hosomi

Key Differences

• is Not Evaluated while Neblina Uacari is Vulnerable.

Taxonomic Classification

Rank		Neblina Uacari
Kingdom	Fungi (Fungi)	Animalia (Animals)
Phylum	Basidiomycota (Club Fungi)	Chordata (Chordates)
Class	Agaricomycetes (Mushrooms)	Mammalia (Mammals)
Order	Agaricales (Gilled Mushrooms)	Primates (Primates)
Family	Entolomataceae	Pitheciidae
Genus	Clitopilus	Cacajao
Species	Clitopilus passeckerianus	Cacajao hosomi

Conservation Status

NE — Not Evaluated

Neblina Uacari

VU — Vulnerable

Physical Characteristics

Attribute		Neblina Uacari
Diet	—	—
Average Lifespan	—	—
Average Length	—	—
Average Weight	—	—

Habitat & Geographic Range

Habitat

Typically found in forest floors, decomposing wood, and soil ecosystems.

Range

Distributed across Norway and Sweden.

Neblina Uacari

Habitat

Typically found in diverse terrestrial and aquatic ecosystems.

Range

Found in Venezuela. Currently classified as Vulnerable on the IUCN Red List, this species faces significant conservation challenges across its range.

Clitopilus passeckerianus is a white-rot agaric fungus in the family Entolomataceae notable for its role as a natural producer of pleuromutilin, a diterpenoid antibiotic compound that serves as the biosynthetic precursor for the veterinary and human antibiotic drugs tiamulin and valnemulin, used to treat Mycoplasma infections in livestock. First described from European woodland habitats, the species produces the characteristic Clitopilus fruiting body: a pale, whitish cap with decurrent, crowded gills becoming pinkish at maturity from angular spores, and a farinaceous odor. Its antibiotic-producing capacity makes C. passeckerianus of significant pharmaceutical interest, and biosynthetic studies of pleuromutilin production have informed synthetic chemistry approaches to antibiotic development. The species inhabits temperate deciduous woodland floors in Europe, fruiting in autumn among leaf litter. Discovery of its pleuromutilin biosynthetic pathway has opened avenues for heterologous expression and semi-synthetic modification aimed at developing novel antibiotics to counter antibiotic-resistant bacterial pathogens.